WO2002064124A3 - Medicament formulation containing a muscarinic agonist - Google Patents
Medicament formulation containing a muscarinic agonist Download PDFInfo
- Publication number
- WO2002064124A3 WO2002064124A3 PCT/EP2002/001374 EP0201374W WO02064124A3 WO 2002064124 A3 WO2002064124 A3 WO 2002064124A3 EP 0201374 W EP0201374 W EP 0201374W WO 02064124 A3 WO02064124 A3 WO 02064124A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formulation containing
- muscarinic agonist
- medicament formulation
- muscarinic
- agonist
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
Abstract
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP02716755A EP1361871A2 (en) | 2001-02-15 | 2002-02-09 | Medicament formulation containing a muscarinic agonist |
MXPA03007272A MXPA03007272A (en) | 2001-02-15 | 2002-02-09 | Medicament formulation containing a muscarinic agonist. |
JP2002563919A JP2004518710A (en) | 2001-02-15 | 2002-02-09 | Pharmaceutical formulations containing muscarinic agonists |
AU2002247705A AU2002247705A1 (en) | 2001-02-15 | 2002-02-09 | Medicament formulation containing a muscarinic agonist |
CA002434976A CA2434976A1 (en) | 2001-02-15 | 2002-02-09 | Medicament formulation containing a muscarinic agonist |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10106971.5 | 2001-02-15 | ||
DE10106971A DE10106971A1 (en) | 2001-02-15 | 2001-02-15 | Drug formulation containing a muscarinic agonist |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2002064124A2 WO2002064124A2 (en) | 2002-08-22 |
WO2002064124A3 true WO2002064124A3 (en) | 2002-12-05 |
Family
ID=7674095
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2002/001374 WO2002064124A2 (en) | 2001-02-15 | 2002-02-09 | Medicament formulation containing a muscarinic agonist |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP1361871A2 (en) |
JP (1) | JP2004518710A (en) |
AR (1) | AR033862A1 (en) |
AU (1) | AU2002247705A1 (en) |
CA (1) | CA2434976A1 (en) |
DE (1) | DE10106971A1 (en) |
MX (1) | MXPA03007272A (en) |
UY (1) | UY27170A1 (en) |
WO (1) | WO2002064124A2 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2140867B2 (en) * | 2007-03-29 | 2023-08-16 | Daiichi Sankyo Company, Limited | Pharmaceutical composition |
WO2010033045A1 (en) * | 2008-09-16 | 2010-03-25 | Igor Anatolievich Pomytkin | Compositions and methods for prevention or treatment of beta amyloid deposition |
CA2793525C (en) | 2010-03-19 | 2014-05-06 | Daiichi Sankyo Company, Limited | Method for improving dissolution of anticoagulant agent |
CA2844604C (en) | 2011-08-10 | 2017-07-18 | Daiichi Sankyo Company, Limited | Pharmaceutical composition containing ethanediamide derivatives |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0370415A1 (en) * | 1988-11-22 | 1990-05-30 | Boehringer Ingelheim Kg | Quinuclidines, their pharmaceutical use and process for their preparation |
WO1998030243A1 (en) * | 1997-01-08 | 1998-07-16 | Warner-Lambert Company | Acetylcholinesterase inhibitors in combination with muscarinic agonists for the treatment of alzheimer's disease |
WO1998046601A1 (en) * | 1997-04-11 | 1998-10-22 | Eli Lilly And Company | Composition for treating pain |
WO1998046225A1 (en) * | 1997-04-11 | 1998-10-22 | Eli Lilly And Company | Method for treating schizophrenia |
DE19851126A1 (en) * | 1998-11-06 | 2000-05-11 | Boehringer Ingelheim Pharma | Use of talsaclidine for treating schizophrenia |
-
2001
- 2001-02-15 DE DE10106971A patent/DE10106971A1/en not_active Withdrawn
-
2002
- 2002-02-09 WO PCT/EP2002/001374 patent/WO2002064124A2/en not_active Application Discontinuation
- 2002-02-09 CA CA002434976A patent/CA2434976A1/en not_active Abandoned
- 2002-02-09 EP EP02716755A patent/EP1361871A2/en not_active Withdrawn
- 2002-02-09 AU AU2002247705A patent/AU2002247705A1/en not_active Abandoned
- 2002-02-09 JP JP2002563919A patent/JP2004518710A/en active Pending
- 2002-02-09 MX MXPA03007272A patent/MXPA03007272A/en unknown
- 2002-02-13 UY UY27170A patent/UY27170A1/en not_active Application Discontinuation
- 2002-02-15 AR ARP020100515A patent/AR033862A1/en not_active Withdrawn
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0370415A1 (en) * | 1988-11-22 | 1990-05-30 | Boehringer Ingelheim Kg | Quinuclidines, their pharmaceutical use and process for their preparation |
WO1998030243A1 (en) * | 1997-01-08 | 1998-07-16 | Warner-Lambert Company | Acetylcholinesterase inhibitors in combination with muscarinic agonists for the treatment of alzheimer's disease |
WO1998046601A1 (en) * | 1997-04-11 | 1998-10-22 | Eli Lilly And Company | Composition for treating pain |
WO1998046225A1 (en) * | 1997-04-11 | 1998-10-22 | Eli Lilly And Company | Method for treating schizophrenia |
DE19851126A1 (en) * | 1998-11-06 | 2000-05-11 | Boehringer Ingelheim Pharma | Use of talsaclidine for treating schizophrenia |
Also Published As
Publication number | Publication date |
---|---|
AR033862A1 (en) | 2004-01-07 |
AU2002247705A1 (en) | 2002-08-28 |
MXPA03007272A (en) | 2003-12-04 |
DE10106971A1 (en) | 2002-08-29 |
WO2002064124A2 (en) | 2002-08-22 |
JP2004518710A (en) | 2004-06-24 |
UY27170A1 (en) | 2002-09-30 |
CA2434976A1 (en) | 2002-08-22 |
EP1361871A2 (en) | 2003-11-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2002213977A1 (en) | Novel anticholinergics, method for the production thereof and use thereof as medicaments | |
AU4048299A (en) | Phenoxylpropanolamines, method for the production thereof and pharmaceutical compositions containing the same | |
AU2002313236A1 (en) | Medicinal compositions | |
AU2002364342A1 (en) | Heteroxylan film-forming composition for making capsules and resulting capsules | |
AU2002302147A1 (en) | Pharmaceutical composition | |
AU2002258221A1 (en) | Medicinal composition | |
AU2002337158A1 (en) | Method for the production of adhesive stamped products | |
AU2001282174A1 (en) | Method for the production of xylitol | |
AU2001263835A1 (en) | Haemostatically active preparation containing vWF and method for the production thereof | |
AU2002345278A1 (en) | Herbal formulation | |
AU3825700A (en) | Pyrido-thieno-diazepines, method for the production thereof and pharmaceutical compositions containing said pyrido-thieno-diazepines | |
WO2002064124A3 (en) | Medicament formulation containing a muscarinic agonist | |
AU2002354460A1 (en) | Medicinal composition | |
AU2002223617A1 (en) | Novel neurokinin antagonists, method for the production thereof and pharmaceutical compositions containing said compounds | |
AU2002351859A1 (en) | Chewing gums and process for the manufacture thereof | |
AU2001231676A1 (en) | Substituted phenylamidines medicaments containing said compounds and method for production thereof | |
AU2002210470A1 (en) | 4-halogenated 17-methylene steroids, method for the production thereof and pharmaceutical compositions containing these compounds | |
AUPR529701A0 (en) | Pharmaceutical composition | |
AU2002346223A1 (en) | Medicinal compositions | |
AU2002361987A1 (en) | Substituted beta-aminoalcohols used as medicaments | |
AU2002242962A1 (en) | Isoquinuclidine derivative, process for producing the same, and medicinal composition containing the same | |
AU2002330163A1 (en) | Dosage form containing a confectionery composition | |
AU2002330476A1 (en) | Medicinal compositions for diabetic neuropathy | |
AU2001279511A1 (en) | Process for obtaining a pharmaceutical composition | |
AU2002321016A1 (en) | Novel 1-amidomethylcarbonyl-piperidine derivatives, method and intermediate products for the production thereof and medicament containing said compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2002716755 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2434976 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002563919 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2003/007272 Country of ref document: MX |
|
WWP | Wipo information: published in national office |
Ref document number: 2002716755 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2002716755 Country of ref document: EP |